Humanin is investigational, with no approved or validated human dosing. There is no reliable schedule to publish, and reported amounts are not standardized. This page explains why, rather than providing a protocol. Any real decision belongs with a qualified clinician.
Overview
People searching for humanin "dosing" are usually looking for a protocol, but for this mitochondrial-derived peptide no validated human regimen exists. What can be discussed responsibly is why amounts are not standardized and what considerations researchers weigh.
Common dosing pattern
There is no established common dosing pattern:
- No regulatory approval defines a human dose, so amounts vary and are not standardized.
- Available research is preclinical and designed to probe mechanism, not to guide personal use.
- Extrapolating from cell or animal studies to a human dose is not scientifically valid.
- Any specific figure circulating online should be treated as unverified rather than as guidance.
Because of this, no start-low schedule or range can be responsibly stated.
How it is handled
In research settings, humanin and its analogs are typically supplied as a lyophilized (freeze-dried) powder for laboratory reconstitution and study. Modified analog forms have been used to make the peptide more convenient to work with, but that reflects experimental tooling, not a defined human product or route.
Why oversight matters
The absence of a stated protocol here is deliberate and reflects the state of the evidence. Only a qualified clinician can weigh an individual's medical circumstances, and no calculator or reference figure can substitute for the clinical trials that would be needed to establish a real dose.